California State University, Long Beach

About: California State University, Long Beach is a education organization based out in Long Beach, California, United States. It is known for research contribution in the topics: Population & Poison control. The organization has 10036 authors who have published 13933 publications receiving 377394 citations. The organization is also known as: Cal State Long Beach & Long Beach State.

Multicomponent self-assembly of a nested Co24 @Co48 metal-organic polyhedral framework.

Abstract: A tale of two polyhedra: two nested Archimedean metal-organic polyhedra, a rhombicuboctahedron (Co(48) cage) and a cuboctahedron (Co(24) cage), have been assembled from two types of cobalt dimers and two complementary ligands. Within the 3D covalent cubic array of outer Co(48) cages and framework lie encapsulated inner Co(24) cages that are linked into a separate "hidden" 3D framework.

Effect of acid etching on the flexural strength of a feldspathic porcelain and a castable glass ceramic

Abstract: This project studied the effect of altering surface topography by chemical etching on the strength of a feldspathic porcelain and castable glass ceramic. Fifty specimens of each ceramic material were subjected to five different etch times (in groups of 10). A silane coupling agent and composite resin cement were applied. Specimens were then subjected to a three-point flexural strength test. Representative specimens were examined under scanning electron microscope to elucidate more information on the effect and the depth of etch. There was no significant difference in the mean flexural strengths between the etched and nonetched groups and no significant difference between the different etching times for either material. Photomicrographs revealed dissimilar etch depths and selective dissolution of the phases. It appears that chemical etching can improve the retention of ceramic laminate veneers without significant loss of strength.

New perspectives on graptolite distributions and their use as indicators of platform margin dynamics

Abstract: Graptolite distributions in Ordovician shelf, slope, and basinal facies in the Great Basin indicate that graptolites were scarce in open oceanic waters oceanward of the Cordilleran shelf margin and that they thrived in waters above the margin. This pattern is consistent with that of most zooplankton in modern oceans. It follows from these observations that the depositional setting of typical graptolitic shale was the area of the sea floor under continental-margin upwelling zones where graptolites flourished and within the oxygen-minimum zone where their rhabdosomes were preserved. With changes over time in relative sea level, deep oceanic circulation, and wind-driven surface circulation, the upwelling and oxygen-minimum zones may have thickened or thinned, migrated landward or oceanward, and expanded laterally, contracted, or even disappeared. The observed graptolite occurrences suggest that the primary graptolite biotope—that is, the habitat of diverse and abundant faunas—was a relatively narrow belt of upwelling waters along, and extending somewhat open oceanward from, the continental margin. Provinces were maintained only to the extent that species could disperse along continental margins. Distribution of typical graptolitic strata may be used to interpret development of continental margins, because such distribution incorporates a signal of sea-level rise or fall, oceanographic changes (especially upwelling), and tectonic events that led to creation and deterioration of upwelling conditions in which graptolites flourished.

Effect of Antidepressant Switching vs Augmentation on Remission Among Patients With Major Depressive Disorder Unresponsive to Antidepressant Treatment: The VAST-D Randomized Clinical Trial.

Abstract: Importance Less than one-third of patients with major depressive disorder (MDD) achieve remission with their first antidepressant. Objective To determine the relative effectiveness and safety of 3 common alternate treatments for MDD. Design, Setting, and Participants From December 2012 to May 2015, 1522 patients at 35 US Veterans Health Administration medical centers who were diagnosed with nonpsychotic MDD, unresponsive to at least 1 antidepressant course meeting minimal standards for treatment dose and duration, participated in the study. Patients were randomly assigned (1:1:1) to 1 of 3 treatments and evaluated for up to 36 weeks. Interventions Switch to a different antidepressant, bupropion (switch group, n = 511); augment current treatment with bupropion (augment-bupropion group, n = 506); or augment with an atypical antipsychotic, aripiprazole (augment-aripiprazole group, n = 505) for 12 weeks (acute treatment phase) and up to 36 weeks for longer-term follow-up (continuation phase). Main Outcomes and Measures The primary outcome was remission during the acute treatment phase (16-item Quick Inventory of Depressive Symptomatology-Clinician Rated [QIDS-C 16 ] score ≤5 at 2 consecutive visits). Secondary outcomes included response (≥50% reduction in QIDS-C 16 score or improvement on the Clinical Global Impression Improvement scale), relapse, and adverse effects. Results Among 1522 randomized patients (mean age, 54.4 years; men, 1296 [85.2%]), 1137 (74.7%) completed the acute treatment phase. Remission rates at 12 weeks were 22.3% (n = 114) for the switch group, 26.9% (n = 136)for the augment-bupropion group, and 28.9% (n = 146) for the augment-aripiprazole group. The augment-aripiprazole group exceeded the switch group in remission (relative risk [RR], 1.30 [95% CI, 1.05-1.60]; P = .02), but other remission comparisons were not significant. Response was greater for the augment-aripiprazole group (74.3%) than for either the switch group (62.4%; RR, 1.19 [95% CI, 1.09-1.29]) or the augment-bupropion group (65.6%; RR, 1.13 [95% CI, 1.04-1.23]). No significant treatment differences were observed for relapse. Anxiety was more frequent in the 2 bupropion groups (24.3% in the switch group [n = 124] vs 16.6% in the augment-aripiprazole group [n = 84]; and 22.5% in augment-bupropion group [n = 114]). Adverse effects more frequent in the augment-aripiprazole group included somnolence, akathisia, and weight gain. Conclusions and Relevance Among a predominantly male population with major depressive disorder unresponsive to antidepressant treatment, augmentation with aripiprazole resulted in a statistically significant but only modestly increased likelihood of remission during 12 weeks of treatment compared with switching to bupropion monotherapy. Given the small effect size and adverse effects associated with aripiprazole, further analysis including cost-effectiveness is needed to understand the net utility of this approach. Trial Registration clinicaltrials.gov Identifier:NCT01421342